Loading resource…

Suchira Gallage, Olivier Govaere, Quentin M. Anstee, Gerald I. Shulman, Frank Tacke, Mathias Heikenwalder
Metabolic dysfunction-associated steatotic liver disease (MASLD), including its progressive form metabolic dysfunction-associated steatohepatitis (MASH), is recognized as a multi-organ disease and the most prevalent chronic liver disease worldwide. The document outlines key pathogenic processes such as insulin resistance, genetic factors, and immune-mediated inflammation that contribute to the disease's progression. It also discusses emerging therapeutic strategies targeting metabolic pathways to improve patient outcomes. The insights provided are crucial for understanding the disease's impact on liver health and potential treatment options.
No account needed